Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.
Drug: Addition of furosemide 20 mg oral bid to baseline regimen
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00240019
|United States, California|
|Kaiser Permanente of Northern California, Santa Clara and San Jose|
|Santa Clara, California, United States, 95051|
|Stanford University Medical Center|
|Stanford, California, United States, 94305|
|Principal Investigator:||Timothy W Meyer, MD||Stanford University|